• VolitionRx Limited Announces Closing of $20 Million Underwritten Public Offering of Common Stock

  • VolitionRx Limited Announces Pricing of $20 Million Underwritten Public Offering of Common Stock

  • VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock

  • VolitionRx Provides a Business Update and Appoints Key Officers to Drive Commercialization Efforts

  • National Taiwan University Hospital Presents Data on Nu.Q™ Assay Performance at the World Conference on Lung Cancer

  • VolitionRx Limited Opens its New Manufacturing Facility in Belgium

  • VolitionRx Limited Awarded an Additional $4 Million in Non-Dilutive Funding

arrow-downarrow-leftarrow-rightarrowchevron-downcircle-link--redcircle-linkcloseplayplus